Expediting MIDD evidence generation to support quizartinib approval in newly diagnosed AML patients

PAGE 33 (2025) Abstr 11445
Glatard A, Mezzalana E, Zheng M, Bergstrand M, Smania G.
ConferenceMIDDOncologyPhase IIIProgram strategies and efficienciesRegulatory interactions

Pharmetheus Affiliates

Portrait-of-Anais-Glatard_Pharmetheus
Senior Consultant

Anaïs Glatard

See bio
Portrait-of-Enrica-Mezzalana_Pharmetheus-1
Senior Consultant

Enrica Mezzalana

See bio
Portrait-of-Martin-Bergstrand_Pharmetheus
Principal Consultant & MIDD Platform Scientific Lead

Martin Bergstrand

See bio
Portrait-of-Giovanni-Smania_Pharmetheus-1
Senior Consultant & Team Leader

Giovanni Smania

See bio